📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts. (2020)

First Author: Middleton M

Attributed to: MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22050

Publication URI: http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22050

Type: Journal Article/Review

Parent Publication: Journal of Clinical Oncology

Issue: 15_suppl